Israeli Stocks: Delek Real Estate, Micromedic, Flowsense, Magal

Israel’s TA-25 Index lost the most in a week, dropping 1.6 percent to 1,246.61 at the 4:30 p.m. close in Tel Aviv. Investors traded about 1.17 billion shekels ($343 million) in shares and convertible securities.

The following stocks rose or fell today. Symbols are in parentheses.

Delek Real Estate Ltd. (DLKR) slid to the lowest level on record, falling 5.5 percent to 0.381 shekel. Isaac Tshuva’s real-estate company reported a loss of 89.5 million shekels after a profit of 29.7 million shekels a year earlier.

Flowsense Medical Ltd. (FLSN) jumped the most since Feb. 6, advancing 7.3 percent to 0.133 shekel. The developer of patient-monitoring equipment said a unit signed an exclusive agreement for Itemedical BV to distribute its Urinfo 2000 system in Holland and Belgium.

Magal Security Systems Ltd. (MAGS) declined the most in more than two years, retreating 10 percent to 11.11 shekels. The stock climbed 17 percent in Tel Aviv yesterday after the company won a $35.5 million order.

Micromedic Technologies Ltd. (MCTC) gained 4.7 percent, the most since Feb. 17, to 3.058 shekels. The developer of biomedical markers said it’s in preliminary talks regarding a possible investment in the company by Bio Light Israel Life Sciences Investments Ltd. (BOLT IT). Bio Light closed unchanged at 0.33 shekel.

Premium P.I.H. Ltd. (PIH IT) soared the most since April 27, climbing 15 percent to 1.078 shekels. The holding company controlled by Yuli Ofer is considering the purchase of a 15 percent stake in Ratio Oil Exploration 1992 LP (RATIL) . Ratio shares were unchanged at 0.413 shekel.

To contact the reporter on this story: Susan Lerner in Jerusalem at slerner2@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.